Drugmaker Regeneron announced they will begin Phase 3 clinical trials of a “double antibody cocktail”.
UPI reports the drug formula is being studied as a possible treatment for COVID-19.
Phase 3 is the last stage of evaluation in the drug approval process and will assess the drug’s ability to prevent infection.
The cocktail, called REGN-COV2 is administered as a single IV infusion.
Researchers will be looking at its ability to treat hospitalized and non-hospitalized patients who have COVID-19.
View at DailyMotion